About Foamix

Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.
Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX102 for the treatment of impetigo, FMX 103 for the treatment of rosacea, and FDX104, our doxycycline foam for the management of acne-like rash, induced by EGFRI anticancer drugs.
Read More

Minocycline Foam

We are developing a topical formulation of minocycline utilizing our proprietary foam technology platform. Our development program consists of three potential indications that we are pursuing: moderate-to-severe acne, impetigo, and rosacea. 
Our phase II results of minocycline foam 4%, applied once-daily, for the treatment of moderate-to-severe acne, showed greater than a 70% reduction in inflammatory acne lesions. We intend to commence Phase III trials for minocycline foam 4% in the United States in 2016


Read More

Recent News

Jan 7

Foamix Announces Positive Results from Phase I Study to Characterize Minocycline Bioavailability of FMX-101 Compared to Solodyn® (Minocycline HCl) Extended-Release Tablets 

Jan 4

Foamix to Present Corporate Overview at the 3rd Annual Dermatology Summit Meeting 

Dec 3

Foamix Announces Positive Top-Line Results from Phase II Study for FDX104 (Doxycycline Foam) in the Prevention of Acneiform Rash Associated with Targeted Antibody Treatments for Colon and Head and Neck Cancers